Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,902 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer.
Akaza H, Uemura H, Tsukamoto T, Ozono S, Ogawa O, Sakai H, Oya M, Namiki M, Fukasawa S, Yamaguchi A, Uemura H, Ohashi Y, Maeda H, Saito A, Takeda K, Naito S. Akaza H, et al. Among authors: yamaguchi a. Int J Clin Oncol. 2016 Aug;21(4):773-782. doi: 10.1007/s10147-016-0952-6. Epub 2016 Jan 21. Int J Clin Oncol. 2016. PMID: 26793974 Free PMC article. Clinical Trial.
The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer.
Ozono S, Ueda T, Hoshi S, Yamaguchi A, Maeda H, Fukuyama Y, Takeda K, Ohashi Y, Tsukamoto T, Naito S, Akaza H. Ozono S, et al. Among authors: yamaguchi a. Jpn J Clin Oncol. 2012 Jun;42(6):477-84. doi: 10.1093/jjco/hys035. Epub 2012 Mar 28. Jpn J Clin Oncol. 2012. PMID: 22457321 Clinical Trial.
Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients.
Akaza H, Yamaguchi A, Matsuda T, Igawa M, Kumon H, Soeda A, Arai Y, Usami M, Naito S, Kanetake H, Ohashi Y. Akaza H, et al. Among authors: yamaguchi a. Jpn J Clin Oncol. 2004 Jan;34(1):20-8. doi: 10.1093/jjco/hyh001. Jpn J Clin Oncol. 2004. PMID: 15020659 Clinical Trial.
Maintenance therapy with bacillus Calmette-Guérin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer.
Hinotsu S, Akaza H, Naito S, Ozono S, Sumiyoshi Y, Noguchi S, Yamaguchi A, Nagamori S, Terai A, Nasu Y, Kume H, Tomita Y, Tanaka Y, Samma S, Uemura H, Koga H, Tsushima T. Hinotsu S, et al. Among authors: yamaguchi a. BJU Int. 2011 Jul;108(2):187-95. doi: 10.1111/j.1464-410X.2010.09891.x. Epub 2010 Dec 22. BJU Int. 2011. PMID: 21176079 Clinical Trial.
2,902 results